I J C R M
International Journal of Contemporary Research In Multidisciplinary

Research Article

Clonal Hematopoiesis: Biological Mechanisms, Clinical Implications, and Therapeutic Opportunities

Himanshu Saini
Faculty of Paramedical & Allied Health Sciences, Motherhood University, Roorkee, Uttarakhand, India

Corresponding Author: * Himanshu Saini

DOI: https://doi.org/10.5281/zenodo.21306888

Abstract

Clonal Hematopoiesis (CH) is an age-associated phenomenon characterized by the expansion of hematopoietic stem and progenitor cells (HSPCs) harbouring somatic mutations. Initially considered a benign consequence of aging, CH—particularly clonal hematopoiesis of indeterminate potential (CHIP)—has emerged as a significant risk factor for hematologic malignancies, cardiovascular disease, and increased mortality. Advances in next-generation sequencing (NGS) technologies have enabled the detection of low-frequency somatic mutations, fundamentally reshaping our understanding of hematopoietic aging and disease evolution. The most commonly implicated genes include *DNMT3A, TET2,* and *ASXL1*, which are involved in epigenetic regulation. Mutations in these genes confer a selective advantage, leading to clonal expansion under conditions of aging, inflammation, and environmental stress. This review discusses the biological basis of CH, its epidemiology, and its role in disease pathogenesis. We further examine diagnostic approaches, clinical implications, and emerging therapeutic strategies, including anti-inflammatory interventions and precision medicine approaches. Finally, we highlight future directions necessary to integrate CH into routine clinical practice.

Manuscript Information

- **ISSN No:** 2583-7397
- **Received:** 05-05-2026
- **Accepted:** 26-06-2026
- **Published:** 30-06-2026
- **IJCRM:**5(3); 2026: 1057-1071

- **Plagiarism Checked:** Yes
- **Peer Review Process:** Yes

How to Cite this Article

Saini H. Clonal Hematopoiesis: Biological Mechanisms, Clinical Implications, and Therapeutic Opportunities. Int J Contemp Res Multidiscip. 2026;5(3):1057-1071.

Access this Article Online

www.multiarticlesjournal.com

KEYWORDS: Clonal hematopoiesis; CHIP; hematopoietic stem cells; ageing; leukaemia; inflammation; cardiovascular disease; epigenetics.

1. INTRODUCTION

Clonal hematopoiesis (CH) refers to the expansion of a genetically distinct subpopulation of hematopoietic cells derived from a single mutated hematopoietic stem cell (HSC) [1]. Under normal physiological conditions, hematopoiesis is a highly regulated process that maintains a diverse pool of blood cells originating from multipotent HSCs [2]. However, with advancing age, these stem cells accumulate somatic mutations due to endogenous replication errors, environmental exposures, and diminished DNA repair mechanisms [3]. Some of these mutations confer a selective growth advantage, enabling the affected clone to expand disproportionately and contribute significantly to blood cell production [4].

With the advent of high-throughput next-generation sequencing technologies, clonal hematopoiesis (CH) has been increasingly recognized as a common feature of aging, even among individuals without overt hematologic abnormalities [5]. These technologies have allowed for the detection of low-frequency somatic mutations in peripheral blood, revealing that clonal expansions are far more prevalent than previously appreciated [6]. Importantly, such findings have shifted the perception of hematopoietic aging from a purely degenerative process to one that involves dynamic clonal selection and competition [7].

Landmark population-based studies have demonstrated that CHIP is rare in younger individuals but becomes increasingly common with age, affecting approximately 10–20% of individuals over the age of 70 [8] [9]. This age-dependent rise highlights the cumulative nature of mutational burden and the role of time in clonal selection. The term clonal hematopoiesis of indeterminate potential (CHIP) was introduced to describe individuals who harbor somatic mutations in genes commonly associated with hematologic malignancies, at a variant allele frequency (VAF) of at least 2%, in the absence of cytopenias or definitive morphological evidence of disease [10].

As a result, mutant clones gain a competitive advantage over their normal counterparts, allowing them to progressively dominate hematopoiesis [11]. In addition to intrinsic genetic changes, extrinsic factors such as chronic inflammation and alterations in the bone marrow microenvironment further promote clonal expansion [12]. The most frequently mutated genes in CHIP include DNMT3A, TET2, and ASXL1, all of which are involved in epigenetic regulation of gene expression Mutations in these genes disrupt normal chromatin architecture and transcriptional control, leading to enhanced self-renewal capacity and impaired differentiation of HSCs [13].

Importantly, CHIP is not merely a benign biomarker of aging but has significant clinical implications. Individuals with CHIP have an approximately 10-fold to 13-fold increased risk of developing hematologic malignancies, particularly acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [14] [15]. Although the absolute risk of transformation remains relatively low on an annual basis at roughly 0.5% to 1.0% per year, the presence of CHIP represents an early pre-malignant state in the continuum of leukemogenesis. Beyond cancer, CHIP has also been strongly associated with an increased risk of cardiovascular disease, including myocardial infarction and stroke. Mechanistic studies suggest that mutant hematopoietic clones contribute to a pro-inflammatory state, thereby accelerating atherosclerosis and vascular injury [16].

Collectively, these observations have redefined clonal hematopoiesis (CH) as a critical intersection between aging, cancer biology, and systemic disease [17]. Understanding the molecular drivers and clinical consequences of clonal hematopoiesis is therefore essential for the development of risk stratification strategies and targeted interventions [18]. Tccchis review aims to provide a comprehensive overview of the biological mechanisms underlying CH, its clinical implications, and emerging therapeutic approaches, with a focus on translating recent discoveries into clinical practice.

2. Biology of Hematopoietic Stem Cells and Aging

2.1 Normal Hematopoiesis

Hematopoiesis is a tightly regulated and dynamic process through which multipotent hematopoietic stem cells (HSCs) generate all mature blood cell lineages, including erythrocytes, leukocytes, and platelets [20]. These HSCs reside within specialized microenvironments in the bone marrow, known as niches, which play a critical role in maintaining stem cell function.

The niche consists of stromal cells, endothelial cells, cytokines, and extracellular matrix components that collectively regulate key HSC properties such as self-renewal, quiescence, proliferation, and differentiation [19]. Complex signaling pathways—including growth factors and cell–cell interactions—ensure that HSCs respond appropriately to physiological demands [20].

Under normal conditions, hematopoiesis maintains a delicate balance between self-renewal and differentiation, ensuring a continuous and adequate supply of blood cells throughout life. This balance is essential to preserve the stem cell pool while simultaneously meeting the body's needs for oxygen transport, immune defense, and hemostasis [21]. Disruption of this tightly controlled process can lead to hematologic disorders, highlighting its fundamental importance in maintaining systemic [22].

2.2 Aging and Hematopoietic Stem Cells

Aging profoundly alters hematopoietic stem cell (HSC) function and contributes to hematopoietic imbalance. Key features of aged HSCs include:

- **Reduced regenerative capacity**, limiting their ability to restore blood cell populations after stress or injury;.
- **Increased self-renewal bias**, which promotes the persistence and expansion of certain stem cell clones.
- **Myeloid-skewed differentiation**, leading to increased production of myeloid cells and reduced lymphoid output, contributing to immune aging [23].
- **Accumulation of DNA damage and somatic mutations**, due to replication errors and declining DNA repair efficiency.

Collectively, these changes create a permissive environment for the emergence and expansion of mutant clones. In addition, age-related alterations in the bone marrow microenvironment—such as changes in stromal support and cytokine signaling—

further influence HSC behaviour. Chronic low-grade systemic inflammation, often referred to as "inflammaging," also plays a crucial role in promoting clonal selection and expansion [23]. These combined intrinsic and extrinsic factors increase the risk of clonal hematopoiesis and the subsequent development of hematologic disorders [24].

3. Molecular Basis of Clonal Hematopoiesis

3.1 Driver Mutations

Clonal hematopoiesis (CH) is driven by somatic mutations in genes commonly associated with hematologic malignancies.
The most frequently mutated genes include:

- **DNMT3A**: plays a key role in DNA methylation and epigenetic regulation.
- **TET2**: involved in DNA demethylation and gene expression control.
- **ASXL1**: functions in chromatin remodeling and transcriptional regulation.

In addition to these, mutations may also occur in other important genes such as:

- **JAK2**: associated with signaling pathways and myeloproliferation
- **TP53**: a tumor suppressor gene regulating cell cycle and apoptosis
- **SF3B1 and SRSF2**: involved in RNA splicing [25].
- These mutations collectively contribute to altered hematopoietic stem cell function and clonal expansion [26] [27].



Figure 1: Overview of Clonal Hematopoiesis Development





Figure 2. Development of clonal hematopoiesis.

Normal hematopoietic stem cells (HSCs) acquire somatic mutations over time . Certain mutations (e.g., *DNMT3A*, *TET2*, *ASXL1*) confer a selective advantage, leading to clonal expansion [28]. With aging and environmental pressures, mutant clones may dominate hematopoiesis and predispose to malignancy and systemic disease [29] [30].

Table 1. Common Gene Mutations in Clonal Hematopoiesis and Their Functional Roles

Gene	Functional Category	Biological Role	Clinical Significance
DNMT3A	Epigenetic regulator	DNA methylation	Most common mutation; early event in clonal hematopoiesis (CH)
TET2	Epigenetic regulator	DNA demethylation	Promotes inflammation; associated with cardiovascular disease (CVD)
ASXL1	Chromatin modifier	Histone modification	Associated with myeloid malignancies
JAK2	Signaling pathway	Cytokine signaling (JAK–STAT pathway)	Linked to myeloproliferative neoplasms (MPNs)
TP53	Tumor suppressor	DNA repair and apoptosis	High-risk mutation; commonly associated with therapy-related CH
SF3B1	RNA splicing	mRNA processing	Associated with specific myelodysplastic syndrome (MDS) subtypes
SRSF2	RNA splicing	Spliceosome function	Associated with poor prognosis in myeloid diseases

3.2 Functional Consequences

Mutations in key epigenetic regulator genes disrupt normal hematopoietic stem cell (HSC) function by altering the regulation of gene expression. These changes lead to several important consequences:

- **Altered gene expression:** Disruption of epigenetic control mechanisms results in abnormal activation or silencing of genes involved in cell growth and differentiation [31].
- **Enhanced self-renewal of HSCs:** Mutant stem cells gain a proliferative advantage, allowing them to expand more efficiently than normal cells.
- **Impaired differentiation:** The ability of HSCs to mature into fully functional blood cells is compromised, leading to an imbalance in blood cell production [32].

For instance, loss-of-function mutations in *TET2* alter the development of blood lineages while simultaneously modifying response dynamics to inflammatory signaling pathways, which further promotes clonal expansion and provides a competitive advantage to mutant clones [33].

3.3 Clonal Expansion

Clonal expansion occurs when mutant hematopoietic stem cells (HSCs) acquire a selective advantage over normal stem cells, allowing them to proliferate more effectively and persist over time. This advantage may be driven by several factors:

- **Intrinsic genetic alterations:** Mutations in key regulatory genes enhance self-renewal capacity and survival of HSCs [36].
- **Environmental factors:** External influences such as toxins, chemotherapy, or radiation can create conditions favoring mutant clones [37].
- **Chronic inflammation:** Persistent inflammatory signals promote the growth and dominance of mutated cells [34] [35].

Over time, these factors enable mutant clones to progressively expand and dominate hematopoiesis. This clonal dominance increases the likelihood of acquiring additional mutations, thereby elevating the risk of progression to hematologic malignancies and other related diseases [34].



Figure 3: Molecular Mechanisms Driving Clonal Expansion



Figure 4. Molecular mechanisms underlying clonal hematopoiesis.

Mutations in epigenetic regulators such as *DNMT3A* (DNA methylation), *TET2* (DNA demethylation), and *ASXL1* (chromatin remodeling) disrupt gene expression programs. These alterations enhance HSC self-renewal and impair differentiation, promoting clonal dominance.

4. Epidemiology and Risk Factors

Clonal hematopoiesis (CH) is strongly associated with aging and has been increasingly recognized as a common biological phenomenon in older populations. Large cohort studies have demonstrated clear age-related trends in its prevalence [38] :

- **<1%** of individuals under 40 exhibit detectable CH

- **Approximately 10%** of individuals over 70 are affected
- **Overall**, prevalence increases steadily with advancing age, reflecting cumulative mutational burden

Table 2. Risk Stratification in Clonal Hematopoiesis (CHIP)

Risk Category	Features	Examples	Clinical Implication
Low Risk	Single mutation, low VAF (<10%)	DNMT3A alone	Low progression risk; routine monitoring
Intermediate Risk	Moderate VAF (10–20%), non-high-risk gene	TET2, ASXL1	Increased monitoring required
High Risk	Multiple mutations, high VAF (>20%)	TP53, SRSF2, SF3B1	High risk of progression to malignancy

Several risk factors contribute to the development and expansion of clonal hematopoiesis (CH):

- **Age:** The strongest predictor, with prevalence rising sharply in individuals over 65–70 years old [39].
- **Smoking:** Induces DNA damage and exerts specific mutational and selective pressures.
- **Obesity and Chronic Inflammation:** Interrelated metabolic and inflammatory changes that promote the expansion and clonal selection of mutated hematopoietic stem cells.
- **Prior Chemotherapy or Radiation Therapy:** Exerts strong selective pressure by reshaping the fitness landscape of the bone marrow environment.
- **Genetic Predisposition:** Inherited germline variants that significantly influence individual susceptibility to developing somatic clones.

Therapy-related CH is particularly significant in cancer survivors. Exposure to cytotoxic treatments can select for resistant mutant clones, often involving DNA damage response genes like *TP53* and *PPM1D*. These specific clones thrive under the selective pressure of chemotherapy or radiation, carrying a substantially higher risk of progression to aggressive therapy-related hematologic malignancies.

5. Clonal Hematopoiesis and Disease Associations

5.1 Hematologic Malignancies

Clonal hematopoiesis of indeterminate potential (CHIP) is associated with a significantly increased risk of hematologic malignancies. Individuals with CHIP have an approximately 10-fold higher relative risk of developing conditions such as acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [40]. However, despite this elevated relative risk, the absolute risk remains low, estimated at around 0.5–1% per year [41].

Progression from CHIP to overt malignancy is influenced by several key factors:

- **Type of mutation:** Certain gene mutations carry higher leukemogenic potential
- **Number of mutations:** Multiple co-occurring mutations increase risk
- **Clone size (VAF):** Larger clones are more likely to progress

Notably, mutations in *TP53* and spliceosome genes (e.g., *SF3B1*, *SRSF2*) are associated with a particularly higher risk of malignant transformation [42].

Table 3. Factors Influencing Progression from CHIP to Hematologic Malignancy

Factor	Description	Impact on Risk
Mutation Type	Gene involved (e.g., TP53 vs DNMT3A)	High-risk gene mutations increase the likelihood of disease progression.
Number of Mutations	Presence of single versus multiple mutations	Multiple mutations are associated with a higher risk of progression.
Clone Size (VAF)	Variant Allele Frequency (VAF), indicating the proportion of mutated cells	Larger clone size (higher VAF) is associated with increased risk.
Age	Advanced age of the individual	Older age increases the cumulative risk of clonal expansion and disease.
Inflammation	Presence of a chronic inflammatory state	Chronic inflammation promotes clonal expansion and elevates progression risk.

5.2 cardiovascular disease

One of the most significant and unexpected findings in recent years is the strong association between clonal hematopoiesis (CH), particularly clonal hematopoiesis of indeterminate potential (CHIP), and cardiovascular disease (CVD). Individuals with CHIP exhibit a markedly increased risk of major cardiovascular events, including:

- **Myocardial infarction**, due to accelerated plaque instability
- **Stroke**, linked to vascular inflammation and thrombosis
- **Atherosclerosis**, driven by chronic inflammatory processes

Mechanistically, mutant hematopoietic clones—especially those harboring *TET2* mutations—play a central role in promoting inflammation. These mutated cells, particularly macrophages, produce elevated levels of pro-inflammatory cytokines such as interleukin-1β (IL-1β) and interleukin-6 (IL-6) [43]. This heightened inflammatory state accelerates the development and progression of atherosclerotic plaques.

As a result, CHIP is now recognized not only as a hematologic risk factor but also as a contributor to systemic vascular disease, highlighting its broader clinical significance beyond malignancy [44].

5.3 Other Associations

Clonal hematopoiesis (CH) has also been increasingly linked to a range of non-hematologic conditions, highlighting its broader systemic impact. Emerging evidence suggests that CH contributes to multiple disease processes beyond malignancy. These associations include:

- **Chronic inflammatory diseases**, where persistent immune activation may both promote and be exacerbated by mutant clones
- **Solid tumors**, potentially through shared risk factors, genomic instability, or altered immune surveillance
- **Increased all-cause mortality**, reflecting the combined effects of malignancy risk, cardiovascular disease, and systemic dysfunction [45].



Figure 5: Clonal Hematopoiesis and Inflammation
(Place in Section 6: Mechanisms Linking CH to Disease)





Figure 6: Inflammatory mechanisms linking clonal hematopoiesis to disease.

Mutant clones, particularly those with *TET2* mutations, promote pro-inflammatory cytokine production (e.g., IL-1β, IL-6). This enhances systemic inflammation, contributing to atherosclerosis, cardiovascular disease, and further clonal expansion.



Figure 7: Clinical Consequences of Clonal Hematopoiesis
(Place in Section 5: Disease Associations)





Figure 8. Clinical consequences of clonal hematopoiesis.

CHIP is associated with increased risk of hematologic malignancies (AML, MDS), cardiovascular disease (atherosclerosis, myocardial infarction), and overall mortality, highlighting its systemic impact.

Table 4. Clinical Associations of Clonal Hematopoiesis

Condition	Association with CH	Proposed Mechanism
Hematologic malignancies	Strong	Accumulation of additional mutations
Cardiovascular disease	Strong	Inflammation (IL-1β, IL-6)
Chronic inflammatory diseases	Moderate	Immune dysregulation
Solid tumors	Emerging	Altered immune surveillance
All-cause mortality	Increased	Combined systemic effects

The underlying mechanisms are thought to involve chronic inflammation, immune dysregulation, and interactions between mutant hematopoietic cells and peripheral tissues . Mutant clones can influence systemic physiology through cytokine production and altered immune responses.

Collectively, these findings underscore that clonal hematopoiesis (CH) is not merely a hematologic condition but a systemic process with wide-ranging clinical consequences, reinforcing its importance in aging and disease biology [46] [47].

6. Mechanisms Linking Clonal Hematopoiesis to Disease

6.1 Inflammatory Signaling

Mutant hematopoietic clones play a critical role in driving a systemic pro-inflammatory state, which contributes to both disease progression and clonal expansion. These effects are particularly evident in clones harboring mutations in epigenetic regulators. Key mechanisms include:

- **TET2-deficient macrophages** produce excess $IL-1\beta$, a potent pro-inflammatory cytokine that amplifies immune activation and promotes tissue damage [48].
- **Chronic inflammation** promotes further clonal expansion, creating a feedback loop in which inflammation favors the survival and proliferation of mutant clones over normal hematopoietic cells [48].

6.2 Immune Dysregulation

Clonal hematopoiesis (CH) significantly alters immune cell function, contributing to impaired host defense and disease susceptibility. Mutations in hematopoietic stem cells give rise to dysfunctional immune cells that exhibit abnormal signaling and reduced regulatory capacity. Key consequences include:

- **Impaired immune surveillance**, where mutated immune cells are less effective at recognizing and eliminating malignant or infected cells.
- **Increased susceptibility to disease**, including infections, inflammatory conditions, and cancer progression.

These defects arise from altered differentiation and function of key immune cell populations such as macrophages, neutrophils, and lymphocytes. In addition, dysregulated cytokine production further disrupts immune homeostasis, promoting chronic inflammation.

Overall, immune dysregulation in CH not only weakens protective immunity but also contributes to a permissive environment for disease development, reinforcing its systemic clinical significance.

6.3 Microenvironmental Interactions

The bone marrow microenvironment, or niche, plays a crucial role in regulating hematopoietic stem cell (HSC) behavior and can significantly influence the expansion of mutant clones in clonal hematopoiesis (CH). Alterations within this niche create conditions that favor the survival and dominance of mutated cells. Key factors include:

- Changes in stromal cell function, which modify the structural and regulatory support provided to HSCs.
- Altered cytokine signaling, leading to enhanced growth signals that preferentially benefit mutant clones.
- Disruption of normal cell–cell interactions, affecting the balance between quiescence, self-renewal, and differentiation.

These microenvironmental changes often occur with aging and chronic inflammation, further reinforcing clonal selection. Mutant HSCs may also actively remodel the niche to their advantage, creating a feedback loop that sustains their expansion.

Overall, the interaction between mutant cells and the bone marrow niche is a key driver of clonal dominance and disease progression.

7. Diagnostic Approaches

7.1 Next-Generation Sequencing

Next-generation sequencing (NGS) is the primary and most sensitive tool for detecting clonal hematopoiesis (CH), enabling identification of low-frequency somatic mutations in peripheral

blood samples. It has revolutionized the early detection and characterization of clonal expansions. Key considerations include:

- **Variant allele frequency (VAF ≥ 2%)**, which serves as the diagnostic threshold for defining clonal hematopoiesis of indeterminate potential (CHIP) [49].
- **Panel-based sequencing**, focusing on genes commonly associated with hematologic malignancies (e.g., *DNMT3A*, *TET2*, *ASXL1*).

NGS allows for precise quantification of clone size and detection of multiple coexisting mutations. However, interpretation requires careful clinical correlation, as the presence of mutations alone does not indicate overt disease. Overall, NGS plays a central role in diagnosis, risk assessment, and monitoring of CH.



Figure 9: Diagnostic Workflow for CHIP

Figure 5. Diagnostic approach to clonal hematopoiesis. NGS-based detection of somatic mutations with VAF ≥2% in the absence of cytopenias or dysplasia defines CHIP. Differentiation from myelodysplastic syndromes requires integration of clinical, morphological, and molecular data.

2 Distinguishing CHIP from Malignancy

Clonal hematopoiesis of indeterminate potential (CHIP) is defined by the presence of somatic mutations in hematopoietic cells without overt evidence of hematologic disease. A key aspect of its diagnosis is the absence of defining pathological features, including:

- **Cytopenias**, meaning normal peripheral blood counts without anemia, leukopenia, or thrombocytopenia
- **Dysplasia**, with no morphological abnormalities observed in bone marrow cells
- **Clinical evidence of malignancy**, such as symptoms, organ involvement, or diagnostic criteria for leukemia or myelodysplastic syndromes (MDS)

Despite these criteria, distinguishing CHIP from early-stage or subclinical MDS remains a significant clinical challenge. Both conditions may share similar genetic mutations, making molecular findings alone insufficient for diagnosis [50].

7.3 Clinical Challenges

The identification of clonal hematopoiesis (CH) in clinical practice presents several important challenges, particularly as genomic testing becomes more widespread. These challenges complicate both interpretation and patient management. Key issues include:

- **Incidental findings during genomic testing**, where CH-associated mutations are unexpectedly detected in individuals undergoing sequencing for unrelated conditions (e.g., tumor profiling), raising questions about disclosure and follow-up [51].
- **Uncertainty in risk prediction**, as not all individuals with CH will progress to malignancy or develop associated diseases, making it difficult to determine prognosis and appropriate monitoring strategies [52].
- **Lack of standardized guidelines**, with no universally accepted protocols for screening, reporting, or managing CH, leading to variability in clinical practice.

8. Clinical Implications

8.1 Risk Stratification

Risk stratification in clonal hematopoiesis is essential for predicting disease progression and guiding clinical management. Assessment is based on several key factors:

- **Mutation type**, as certain genes (e.g., *TP53*, *JAK2*, and spliceosome genes like *SRSF2*) are associated with a significantly higher risk of leukemic transformation.
- **Number of mutations**, with multiple coexisting mutations indicating greater genomic instability and a higher propensity for progression.
- **Clone size (variant allele frequency, VAF)**, where larger clones (typically ≥ 10%) reflect greater clonal dominance and a steeper trajectory toward malignancy.

High-risk features include the presence of multiple mutations and a high VAF, both of which are linked to an increased likelihood of progression to hematologic malignancies. Integrating these factors helps identify individuals who may benefit from closer monitoring and early intervention strategies [53].

8.2 Monitoring

Patients with clonal hematopoiesis of indeterminate potential (CHIP) may benefit from regular monitoring to detect early disease progression. Recommended approaches include:

- **Periodic blood counts**, to identify emerging cytopenias or abnormalities.
- **Serial molecular testing**, to track changes in clone size (VAF) and mutation profile.

8.3 Ethical Considerations

The detection of clonal hematopoiesis of indeterminate potential (CHIP) raises several important ethical considerations in clinical practice:

- **Disclosure of incidental findings**, particularly when mutations are identified during unrelated germline or somatic tumor testing.
- **Psychological impact on patients**, including anxiety about potential cancer risk or "pre-malignant" status.
- **Uncertain clinical significance**, as the vast majority of individuals with CHIP will never progress to a hematologic disease.

These challenges require careful communication, informed consent, and balanced decision-making to support patients while avoiding unnecessary distress.

These interventions aim to reduce background vascular inflammation and overall disease burden, potentially limiting the clinical impact of CH on long-term health outcomes. While these strategies are not specific to CH, they are currently the most practical and evidence-based approaches for minimizing associated risks in affected individuals.

8.4 Future Therapies

Emerging therapeutic strategies in clonal hematopoiesis (CH) aim to move beyond observation toward targeted and potentially curative interventions. These innovative approaches include:

- **Gene editing (CRISPR-based strategies)**, which offer the long-term potential to directly correct or eliminate disease-driving mutations at the hematopoietic stem cell level.
- **Precision medicine approaches**, designed to target specific mutations (e.g., *TET2*, *DNMT3A*, *TP53*) using tailored therapies based on an individual's genetic profile.
- **Immunomodulatory therapies**, which seek to restore normal immune function and microenvironmental surveillance, thereby limiting clonal expansion and its systemic effects.

While these approaches remain largely experimental, they represent a promising future direction in the management of CH. Continued research and clinical trials will be essential to determine their safety, feasibility, and long-term effectiveness in preventing disease progression.



Figure 10: Therapeutic Strategies and Future Directions



Figure 11. Therapeutic strategies targeting clonal hematopoiesis.

Potential interventions include targeting mutant clones (epigenetic therapy), reducing inflammation (IL-1β inhibitors), managing cardiovascular risk, and emerging approaches such as gene editing and precision medicine.

10. Future Directions

Key areas for future research in clonal hematopoiesis (CH) are critical for improving risk assessment, clinical management, and therapeutic development. Several priorities have been identified:

- **Longitudinal studies to define progression risk:** Large, long-term cohort studies are needed to better understand which individuals with CH are most likely to progress to hematologic malignancies or develop associated conditions such as cardiovascular disease [54].. These studies will help clarify the natural history of CH.
- **Development of predictive models:** Integrating genetic, clinical, and environmental data into robust risk prediction models will enable more accurate stratification of patients based on their likelihood of disease progression and complications.
- **Integration of CH into clinical guidelines:** As evidence accumulates, there is a growing need to incorporate CH into standardized clinical frameworks, including recommendations for screening, monitoring, and management [55]..
- **Clinical trials targeting CHIP-associated pathways:** Prospective trials are essential to evaluate targeted therapies, anti-inflammatory approaches, and novel interventions aimed at reducing clonal expansion and disease risk [56].

Advancing these areas will be essential for translating current knowledge into effective, evidence-based clinical practice.

Artificial intelligence and machine learning may enhance risk prediction and personalize patient management [57].



Figure 12: Clonal Evolution Model



Figure 13. Clonal evolution and progression to malignancy.

Clonal hematopoiesis evolves through sequential acquisition of mutations. While many clones remain stable, additional genetic hits may drive progression to overt hematologic malignancies.

11. CONCLUSION

Clonal hematopoiesis (CH) represents a major paradigm shift in the field of hematology, fundamentally redefining the relationship between aging, cancer, and systemic disease. Once viewed as a benign and incidental consequence of aging, CH is now recognized as a clinically significant condition associated with increased risks of hematologic malignancies, cardiovascular disease, and overall mortality.

Advances in high-throughput genomic technologies have enabled the early detection of CH, even in asymptomatic individuals, offering new opportunities for risk assessment and preventive care. However, significant challenges remain, particularly in accurately stratifying patients based on progression risk and establishing standardized clinical management guidelines.

Despite these limitations, CH provides a unique window into early disease evolution and the interplay between genetics, inflammation, and environmental factors. Continued research is essential to refine predictive models, develop targeted therapies, and validate preventive strategies. Ultimately, integrating CH into precision medicine frameworks will be crucial for improving patient outcomes and advancing personalized healthcare.

ACKNOWLEDGEMENT

The author is grateful to Faculty of Paramedical & Allied Health Sciences, Motherhood University Roorkee, for their support throughout this study

FUNDINGS SOURCE

The study had no funding source.

CONFLICT OF INTEREST

Authors declare that they have no conflict of inter est.

REFERENCES

1. Busque L, Buscarlet M, Mollica L, Levine RL. Concise review: age-related clonal hematopoiesis: stem cells tempting the devil. Stem Cells. 2018;36(12):1287-94. doi:10.1002/stem.2845
2. Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. J Clin Invest. 2024;134. doi:10.1172/jci180065
3. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366. doi:10.1126/science.aan4673
4. Jan M, Ebert BL, Jaiswal S. Clonal hematopoiesis. Semin Hematol. 2017;54:43-50. doi:10.1053/j.seminhematol.2016.10.002
5. Park SJ, Bejar R. Clonal hematopoiesis in aging. Curr Stem Cell Rep. 2018;4:209-19. doi:10.1007/s40778-018-0133-9
6. Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. J Clin Invest. 2024;134. doi:10.1172/jci180065
7. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366. doi:10.1126/science.aan4673
8. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87. doi:10.1056/nejmoa1409405
9. Jaiswal S, Fontanillas P, Flannick J, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-98. doi:10.1056/nejmoa1408617
10. Steensma DP, Bejar R, Jaiswal S, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16. doi:10.1182/blood-2015-03-631747
11. Cobo I, Tanaka T, Glass CK, Yeang C. Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. Curr Opin Hematol. 2021;29(1):1-7. doi:10.1097/moh.0000000000000688
12. Haring B, Wissel S, Manson JE. Somatic mutations and clonal hematopoiesis as drivers of age-related cardiovascular risk. Curr Cardiol Rep. 2022;24(1):1049-58. doi:10.1007/s11886-022-01724-2
13. Reed SC, Croessmann S, Park BH. CHIP happens: clonal hematopoiesis of indeterminate potential and its

relationship to solid tumors. Clin Cancer Res. 2022;29(14):1403-11. doi:10.1158/1078-0432.ccr-22-2598
14. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87. doi:10.1056/nejmoa1409405
15. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, et al. Age-related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488-98. doi:10.1056/nejmoa1408617
16. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366(6465):eaan4673. doi:10.1126/science.aan4673
17. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366. doi:10.1126/science.aan4673
18. Petrone G, Turker I, Natarajan P, et al. Clinical and therapeutic implications of clonal hematopoiesis. Annu Rev Genomics Hum Genet. 2024;25:329-51. doi:10.1146/annurev-genom-120722-100409
19. Anthony BA, Link DC. Regulation of hematopoietic stem cells by bone marrow stromal cells. Trends Immunol. 2014;35(1):32-7. doi:10.1016/j.it.2013.10.002
20. Chotinantakul K, Leeanansaksiri W. Hematopoietic stem cell development, niches, and signaling pathways. Bone Marrow Res. 2012;2012:1-16. doi:10.1155/2012/270425
21. Kandarakov O, Belyavsky A, Semenova E. Bone marrow niches of hematopoietic stem and progenitor cells. Int J Mol Sci. 2022;23(8):4462. doi:10.3390/ijms23084462
22. Kwon M, Kim BS, Yoon S, Oh SO, Lee D. Hematopoietic stem cells and their niche in bone marrow. Int J Mol Sci. 2024;25(13):6837. doi:10.3390/ijms25136837
23. Leimkühler NB, Schneider RK. Inflammatory bone marrow microenvironment. Hematology. 2019;2019(1):294-302. doi:10.1182/hematology.2019000045
24. Mejia-Ramirez E, Florian MC. Understanding intrinsic hematopoietic stem cell aging. Haematologica. 2019;105(1):22-37. doi:10.3324/haematol.2018.211342
25. Verovskaya EV, Dellorusso PV, Passegué E. Losing sense of self and surroundings: hematopoietic stem cell aging and leukemic transformation. Trends Mol Med. 2019;25(6):494-515. doi:10.1016/j.molmed.2019.04.006
26. Ariste O, de la Grange P, Veitia RA. Recurrent missense variants in clonal hematopoiesis-related genes present in the general population. Clin Genet. 2022;103(3):247-51. doi:10.1111/cge.14259
27. Kaner J, Desai P, Mencia-Trinchant N, Guzman ML, Roboz GJ, Hassane DC. Clonal hematopoiesis and premalignant diseases. Cold Spring Harb Perspect Med. 2019;10(10):a035675. doi:10.1101/cshperspect.a035675
28. Marshall CH, Gondek LP, Luo J, Antonarakis ES. Clonal hematopoiesis of indeterminate potential in patients with solid tumor malignancies. Cancer Res. 2022;82(22):4107-13. doi:10.1158/0008-5472.can-22-0985
29. Cobo I, Tanaka T, Glass CK, Yeang C. Clonal hematopoiesis driven by DNMT3A and TET2 mutations: role in monocyte and macrophage biology and atherosclerotic cardiovascular disease. Curr Opin Hematol. 2021;29(1):1-7. doi:10.1097/moh.0000000000000688
30. Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. J Clin Invest. 2024;134(19). doi:10.1172/jci180065
31. Genovese G, Kähler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87. doi:10.1056/nejmoa1409405
32. An J, Ko M. Epigenetic modification of cytosines in hematopoietic differentiation and malignant transformation. Int J Mol Sci. 2023;24(2):1727. doi:10.3390/ijms24021727
33. Huerga Encabo H, Aramburu IV, Garcia-Albornoz M, Piganeau M, Wood H, Song A, et al. Loss of TET2 in human hematopoietic stem cells alters the development and function of neutrophils. Cell Stem Cell. 2023;30(6):781-799.e9. doi:10.1016/j.stem.2023.05.004
34. Moran-Crusio K, Reavie L, Shih A, Abdel-Wahab O, Ndiaye-Lobry D, Lobry C, et al. Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell. 2011;20(1):11-24. doi:10.1016/j.ccr.2011.06.001
35. Asada S, Kitamura T. Clonal hematopoiesis and associated diseases: a review of recent findings. Cancer Sci. 2021;112(10):3962-71. doi:10.1111/cas.15094
36. Avagyan S, Zon LI. Clonal hematopoiesis and inflammation – the perpetual cycle. Trends Cell Biol. 2023;33(8):695-707. doi:10.1016/j.tcb.2022.12.001
37. Challen G, Goodell MA. Clonal hematopoiesis: mechanisms driving dominance of stem cell clones. Blood. 2020. doi:10.1182/blood.2020006510
38. Pendse S, Loeffler D. Decoding clonal hematopoiesis: emerging themes and novel mechanistic insights. Cancers (Basel). 2024;16(15):2634. doi:10.3390/cancers16152634
39. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366. doi:10.1126/science.aan4673
40. Dunn WG, McLoughlin MA, Vassiliou GS. Clonal hematopoiesis and hematological malignancy. J Clin Invest. 2024;134. doi:10.1172/jci180065
41. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(24):2477-87. doi:10.1056/nejmoa1409405
42. Marnell CS, Bick A, Natarajan P. Clonal hematopoiesis of indeterminate potential (CHIP): linking somatic mutations, hematopoiesis, chronic inflammation and cardiovascular disease. J Mol Cell Cardiol. 2021;161:98-105. doi:10.1016/j.yjmcc.2021.07.004
43. Fuster JJ, MacLauchlan S, Zuriaga MA, Polackal MN, Ostriker AC, Chakraborty R, et al. Clonal hematopoiesis associated with TET2 deficiency accelerates atherosclerosis development in mice. Science. 2017;355(6327):842-7. doi:10.1126/science.aag1381
44. Oren O, Small AM, Libby P. Clonal hematopoiesis and atherosclerosis. J Clin Invest. 2024;134(2). doi:10.1126/jci180066

45. Stein A, Metzeler K, Kubasch AS, Rommel KP, Desch S, Buettner P, et al. Clonal hematopoiesis and cardiovascular disease: deciphering interconnections. Basic Res Cardiol. 2022;117(1). doi:10.1007/s00395-022-00969-w
46. Asada S, Kitamura T. Clonal hematopoiesis and associated diseases: a review of recent findings. Cancer Sci. 2021;112:3962-71. doi:10.1111/cas.15094
47. Jaiswal S, Ebert BL. Clonal hematopoiesis in human aging and disease. Science. 2019;366. doi:10.1126/science.aan4673
48. Avagyan S, Zon LI. Clonal hematopoiesis and inflammation – the perpetual cycle. Trends Cell Biol. 2023;33(8):695-707. doi:10.1016/j.tcb.2022.12.001
49. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16. doi:10.1182/blood-2015-03-631747
50. Genovese G, et al. Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014;371(26):2477-87.
51. Heuser M, et al. Clonal hematopoiesis of indeterminate potential: KLH clinical practice guidelines. Ann Oncol. 2020;31(11):1430-41.
52. Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119-31.
53. Steensma DP, et al. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.
54. Gajagowni S, Hopkins S, Qadeer Y, et al. Clonal hematopoiesis of indeterminate potential and cardiovascular disease: pathogenesis, clinical presentation, and future directions. Prog Cardiovasc Dis. 2024;86:79-85. doi:10.1016/j.pcad.2024.09.001
55. Park SJ, Bejar R. Clonal hematopoiesis in cancer. Exp Hematol. 2020;83:105-12. doi:10.1016/j.exphem.2020.02.001
56. Raddatz MA, Pershad Y, Parker AC, Bick AG. Clonal hematopoiesis of indeterminate potential and cardiovascular health. Cardiol Clin. 2025;43(1):13-23. doi:10.1016/j.ccl.2024.08.004
57. Arango-Argoty G, Haghighi M, Sun GJ, et al. An artificial intelligence-based model for prediction of clonal hematopoiesis mutants in cell-free DNA samples. bioRxiv. 2024. doi:10.1101/2024.12.11.627785

About the Author

Himanshu Saini is a faculty member in the Faculty of Paramedical & Allied Health Sciences at Motherhood University, Roorkee, Uttarakhand, India. His academic interests include allied health sciences, medical education, clinical research, and public health. He is committed to advancing healthcare education through innovative teaching, interdisciplinary research, and evidence-based practices.